Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function: possible links between diabetes and atherosclerosis.
People with diabetes experience chronic hyperglycemia and are at a high risk of developing atherosclerosis and microvascular disease. Reactions of glucose, or aldehydes derived from glucose (e.g. methylglyoxal, glyoxal, or glycolaldehyde), with proteins result in glycation that ultimately yield advanced glycation end products (AGE). AGE are present at elevated levels in plasma and atherosclerotic lesions from people with diabetes, and previous in vitro studies have postulated that the presence of these materials is deleterious to cell function. This accumulation of AGE and glycated proteins within cells may arise from either increased formation and/or ineffective removal by cellular proteolytic systems, such as the proteasomes, the major multi-enzyme complex that removes proteins within cells. In this study it is shown that whilst high glucose concentrations fail to modify proteasome enzyme activities in J774A.1 macrophage-like cell extracts, reactive aldehydes enhanced proteasomal enzyme activities. In contrast BSA, pre-treated with high glucose for 8 weeks, inhibited both the chymotrypsin-like and caspase-like activities. BSA glycated using methylglyoxal or glycolaldehyde, also inhibited proteasomal activity though to differing extents. This suppression of proteasome activity by glycated proteins may result in further intracellular accumulation of glycated proteins with subsequent deleterious effects on cellular function.
Moheimani
Fatemeh
F
Free Radical Group, The Heart Research Institute, 7 Eliza Street, Newtown NSW, 2042 Australia.
Morgan
Philip E
PE
van Reyk
David M
DM
Davies
Michael J
MJ
D000447:Aldehydes / Q000378:metabolism; D000818:Animals; D050197:Atherosclerosis / Q000209:etiology* / Q000378:metabolism*; D002417:Cattle; D002460:Cell Line; D003920:Diabetes Mellitus / Q000209:etiology* / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D012709:Serum Albumin / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000378:metabolism; D000093423:Glycated Serum Albumin
D000447:Aldehydes; D017127:Glycation End Products, Advanced; D012709:Serum Albumin; D012710:Serum Albumin, Bovine; D046988:Proteasome Endopeptidase Complex; D005947:Glucose; D000093423:Glycated Serum Albumin